Cell MedX Corp. 4
4 · Cell MedX Corp. · Filed Dec 1, 2014
Insider Transaction Report
Form 4
Cell MedX Corp.CMXC
ARNETT JEAN M
DirectorVP, Corporate Strategy10% Owner
Transactions
- Award
Stock Options (Right to Buy)
2014-11-25+1,250,000→ 1,250,000 totalExercise: $0.05→ Common Stock (1,250,000 underlying) - Award
Stock Options (Right to Buy)
2014-11-25+1,250,000→ 1,250,000 totalExercise: $0.05→ Common Stock (1,250,000 underlying) - Award
Stock Options (Right to Buy)
2014-11-25+1,250,000→ 1,250,000 totalExercise: $0.05→ Common Stock (1,250,000 underlying) - Award
Stock Options (Right to Buy)
2014-11-25+2,500,000→ 2,500,000 totalExercise: $0.05→ Common Stock (2,500,000 underlying) - Award
Stock Options (Right to Buy)
2014-11-25+2,500,000→ 2,500,000 totalExercise: $0.05→ Common Stock (2,500,000 underlying) - Award
Stock Options (Right to Buy)
2014-11-25+1,250,000→ 1,250,000 totalExercise: $0.05→ Common Stock (1,250,000 underlying)
Footnotes (7)
- [F1]The Options will vest upon the design and commencement of first clinical trials.
- [F2]The Options will vest upon the completion of first clinical trials and delivery of final white paper for first clinical trials.
- [F3]The Options will vest upon the design and commencement of second clinical trials.
- [F4]The Options will vest upon the completion of second clinical trials and delivery of final white paper for second clinical trials.
- [F5]The Options will vest upon the design and commencement of third clinical trials
- [F6]The Options will vest upon the completion of the third clinical trials and delivery of final white paper for third clinical trials.
- [F7]Options that have vested will expire 5 years after vesting. Options that have not vested will expire on 12/31/2019.